Teladoc (NYSE:TDOC) had its price objective hoisted by analysts at SunTrust Banks to $100.00 in a research note issued on Monday, The Fly reports. The firm presently has a “buy” rating on the health services provider’s stock. SunTrust Banks’ target price indicates a potential upside of 23.76% from the company’s current price.

Several other equities research analysts have also issued reports on TDOC. Oppenheimer increased their target price on shares of Teladoc from $59.00 to $68.00 and gave the stock an “outperform” rating in a report on Thursday, August 2nd. Canaccord Genuity reissued a “buy” rating and issued a $70.00 target price on shares of Teladoc in a report on Thursday, August 2nd. Piper Jaffray Companies increased their target price on shares of Teladoc to $84.00 and gave the stock an “overweight” rating in a report on Friday. MED increased their target price on shares of Teladoc to $56.00 and gave the stock a “hold” rating in a report on Thursday, June 7th. Finally, Citigroup increased their target price on shares of Teladoc from $80.00 to $88.00 and gave the stock a “buy” rating in a report on Friday. One analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Teladoc presently has an average rating of “Buy” and an average target price of $67.80.

Shares of NYSE TDOC traded up $2.70 during midday trading on Monday, hitting $80.80. 12,598 shares of the company’s stock traded hands, compared to its average volume of 1,062,756. Teladoc has a 1 year low of $27.30 and a 1 year high of $79.64. The firm has a market capitalization of $5.43 billion, a P/E ratio of -48.85 and a beta of 0.57. The company has a quick ratio of 3.14, a current ratio of 3.14 and a debt-to-equity ratio of 0.58.

Teladoc (NYSE:TDOC) last released its quarterly earnings results on Wednesday, August 1st. The health services provider reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.01. The firm had revenue of $94.60 million during the quarter, compared to analyst estimates of $91.56 million. Teladoc had a negative net margin of 37.78% and a negative return on equity of 19.10%. The business’s revenue for the quarter was up 112.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.28) EPS. equities research analysts anticipate that Teladoc will post -1.51 EPS for the current year.

In other news, CEO Jason N. Gorevic sold 25,000 shares of the stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $75.05, for a total transaction of $1,876,250.00. Following the completion of the transaction, the chief executive officer now directly owns 536,184 shares in the company, valued at approximately $40,240,609.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Adam C. Vandervoort sold 24,250 shares of the stock in a transaction that occurred on Monday, July 9th. The shares were sold at an average price of $64.28, for a total value of $1,558,790.00. Following the transaction, the insider now owns 12,272 shares of the company’s stock, valued at $788,844.16. The disclosure for this sale can be found here. Insiders sold a total of 268,781 shares of company stock valued at $18,083,387 over the last 90 days. 3.95% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Teladoc by 9.0% during the 2nd quarter. BlackRock Inc. now owns 5,318,850 shares of the health services provider’s stock valued at $308,759,000 after acquiring an additional 437,136 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Teladoc by 1.4% during the 1st quarter. JPMorgan Chase & Co. now owns 4,678,836 shares of the health services provider’s stock valued at $188,559,000 after acquiring an additional 65,383 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Teladoc by 82.8% during the 2nd quarter. Bank of America Corp DE now owns 1,883,185 shares of the health services provider’s stock valued at $109,318,000 after acquiring an additional 853,076 shares during the last quarter. Zevenbergen Capital Investments LLC boosted its position in shares of Teladoc by 3.9% during the 2nd quarter. Zevenbergen Capital Investments LLC now owns 1,629,170 shares of the health services provider’s stock valued at $94,574,000 after acquiring an additional 61,325 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC boosted its position in shares of Teladoc by 6.0% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,477,276 shares of the health services provider’s stock valued at $85,756,000 after acquiring an additional 83,319 shares during the last quarter.

About Teladoc

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Article: Index Funds

The Fly

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.